Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer: A case report

RATIONALE. Neo-adjuvant systemic therapy includes endocrine therapy and chemotherapy, which is widely used. Luminal breast cancer is resistant to chemotherapy and is more likely to not respond to chemotherapy before surgery. Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor. Palbociclib wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Sung Ui, Jung, Minjung, Choi, Jin Hyuk, Jeon, Chang Wan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036054/
https://www.ncbi.nlm.nih.gov/pubmed/33832078
http://dx.doi.org/10.1097/MD.0000000000025175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036054/
https://www.ncbi.nlm.nih.gov/pubmed/33832078
http://dx.doi.org/10.1097/MD.0000000000025175

Ejemplares similares